Core Insights - Fangzhou Inc. has achieved a significant milestone with the successful launch of its "XingJie" Large Language Model (XJ LLM), enhancing its AI-driven chronic disease management capabilities [2][3] - The company aims to integrate advanced AI technologies with professional medical services to provide smarter, more accessible, and personalized healthcare solutions [2][8] Company Developments - Fangzhou's XJ LLM has completed the National Generative AI Service Filing, solidifying its leadership in AI-powered chronic disease management [3] - The dual-model architecture, including the XS LLM and XJ LLM, supports comprehensive management across various specialty disease areas, enhancing the AI+H2H ecosystem [5] - The XJ LLM is designed to improve service experience through technological advancements, application transformation, and operational efficiency, enabling natural interactions and autonomous task execution [4] Strategic Partnerships - The company has formed strategic partnerships with leading pharmaceutical firms such as Novo Nordisk, Innovent Biologics, and Fosun Pharma to advance AI-enabled disease management frameworks [7] User Base and Market Position - As of June 30, 2025, Fangzhou serves 52.8 million registered users and 229,000 physicians, positioning itself as a leading online chronic disease management platform in China [9]
Fangzhou’s “XingJie” LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations